Investigational therapy ulefnersen demonstrated statistically significant improvements in functional impairment and survival, marking a potential breakthrough for a rare and rapid form of ALS.
No benefit seen in primary end point of median clonal growth rate, but benefits seen in terms of secondary outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results